BR9908545A - Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica - Google Patents
Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêuticaInfo
- Publication number
- BR9908545A BR9908545A BR9908545-3A BR9908545A BR9908545A BR 9908545 A BR9908545 A BR 9908545A BR 9908545 A BR9908545 A BR 9908545A BR 9908545 A BR9908545 A BR 9908545A
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- compound
- pharmaceutical composition
- formula
- piperidine derivative
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003053 piperidines Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 2
- 102000007317 Farnesyltranstransferase Human genes 0.000 abstract 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
"DERIVADO DE PIPERIDINA, PROCESSO PARA A PREPARAçãO DO MESMO, COMPOSTO, PROCESSO PARA A PREPARAçãO DO MESMO, E, COMPOSIçãO FARMACêUTICA" A presente invenção diz respeito a um novo derivado de piperidina representado pela fórmula (1), que mostra uma atividade inibitória contra a farnesil transferase ou seus sais farmaceuticamente aceitáveis, em que A, E e G são como definidos no relatório descritivo; a um processo para a preparação do composto de fórmula (1); a um intermediário que é usado na preparação do composto de fórmula (1); e a uma composição farmacêutica que compreende o composto de fórmula (1) como um ingrediente ativo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR19980002776 | 1998-02-02 | ||
| KR1019980002777A KR100388789B1 (ko) | 1998-02-02 | 1998-02-02 | 피롤구조를갖는파네실전이효소억제제및그의제조방법 |
| KR1019980028340A KR100388792B1 (ko) | 1998-02-02 | 1998-07-14 | 피페리딘구조를갖는파네실전이효소억제제및그의제조방법 |
| KR10-1998-0032150A KR100388794B1 (ko) | 1998-08-07 | 1998-08-07 | 피페리딘구조를갖는파네실전이효소억제제및그의제조방법 |
| PCT/KR1999/000051 WO1999038862A1 (en) | 1998-02-02 | 1999-02-01 | Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9908545A true BR9908545A (pt) | 2001-10-02 |
Family
ID=27483262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9908545-3A BR9908545A (pt) | 1998-02-02 | 1999-02-01 | Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6436960B1 (pt) |
| EP (1) | EP1058683B1 (pt) |
| JP (1) | JP3283032B2 (pt) |
| CN (1) | CN1158277C (pt) |
| AT (1) | ATE229017T1 (pt) |
| AU (1) | AU745855B2 (pt) |
| BR (1) | BR9908545A (pt) |
| CA (1) | CA2320233C (pt) |
| DE (1) | DE69904302T2 (pt) |
| ES (1) | ES2185307T3 (pt) |
| PT (1) | PT1058683E (pt) |
| WO (1) | WO1999038862A1 (pt) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100388792B1 (ko) * | 1998-02-02 | 2003-09-22 | 주식회사 엘지생명과학 | 피페리딘구조를갖는파네실전이효소억제제및그의제조방법 |
| KR100388794B1 (ko) * | 1998-08-07 | 2003-10-10 | 주식회사 엘지생명과학 | 피페리딘구조를갖는파네실전이효소억제제및그의제조방법 |
| JP2002543074A (ja) * | 1999-04-13 | 2002-12-17 | エルジー シーアイ リミテッド | ピロール構造を有するファネシル転移酵素阻害剤及びその製造方法 |
| KR20010063274A (ko) * | 1999-12-22 | 2001-07-09 | 성재갑 | 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물 |
| US7035932B1 (en) * | 2000-10-27 | 2006-04-25 | Eric Morgan Dowling | Federated multiprotocol communication |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| ATE441417T1 (de) | 2002-12-20 | 2009-09-15 | Glaxo Group Ltd | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten |
| KR20110094361A (ko) | 2003-04-11 | 2011-08-23 | 메디뮨 엘엘씨 | 재조합 ｉｌ９ 항체 및 그의 용도 |
| US20050048617A1 (en) | 2003-08-18 | 2005-03-03 | Medimmune, Inc. | Humanization of antibodies |
| CA2541509C (en) * | 2003-10-17 | 2014-06-10 | Incyte Corporation | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| WO2006047639A2 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| EP1869192B1 (en) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Framework-shuffling of antibodies |
| KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
| EA021255B1 (ru) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Антагонистические моноклональные антитела человека, специфичные в отношении light человека |
| US20100209434A1 (en) | 2007-03-30 | 2010-08-19 | Medimmune, Llc | Antibody formulation |
| EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| CN104812775B (zh) | 2012-07-25 | 2019-05-03 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
| JP2015533832A (ja) | 2012-10-09 | 2015-11-26 | アイジェニカ バイオセラピューティクス インコーポレイテッド | 抗Ｃ１６ｏｒｆ５４抗体およびその使用方法 |
| SG10201708143QA (en) | 2013-06-06 | 2017-11-29 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| WO2015053871A2 (en) | 2013-08-26 | 2015-04-16 | MabVax Therapeutics, Inc. | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| KR102226248B1 (ko) | 2014-06-04 | 2021-03-12 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체 |
| WO2016094837A2 (en) | 2014-12-11 | 2016-06-16 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
| KR102740384B1 (ko) | 2015-03-03 | 2024-12-06 | 키맵 리미티드 | 항체, 용도 및 방법 |
| MX2018006613A (es) | 2015-12-02 | 2019-01-30 | Stcube & Co Inc | Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos. |
| EP3383908A1 (en) | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| KR20250036941A (ko) | 2017-05-31 | 2025-03-14 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
| WO2018222685A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
| EP3635007A1 (en) | 2017-06-06 | 2020-04-15 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
| CN111630069B (zh) | 2017-10-13 | 2024-05-31 | 勃林格殷格翰国际有限公司 | 针对Thomsen-nouvelle(Tn)抗原的人抗体 |
| IL280199B2 (en) | 2018-07-20 | 2025-08-01 | Pf Medicament | Receptor for vista |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE903957A1 (en) * | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
| EP0632808A1 (en) * | 1992-03-25 | 1995-01-11 | Pfizer Limited | Antiviral peptides |
| GB9312806D0 (en) * | 1993-06-22 | 1993-08-04 | Boots Co Plc | Therapeutic agents |
| AU715603B2 (en) * | 1996-04-03 | 2000-02-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2249601A1 (en) * | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibitors of farnesyl-protein transferase |
| JP2000504023A (ja) * | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | 癌治療方法 |
| WO1997036890A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0891353A4 (en) * | 1996-04-03 | 2001-08-08 | Merck & Co Inc | FARNESYL PROTEIN TRANSFERASE INHIBITORS |
| US6268363B1 (en) * | 1997-11-28 | 2001-07-31 | Lg Chemical Ltd. | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof |
-
1999
- 1999-02-01 DE DE69904302T patent/DE69904302T2/de not_active Expired - Fee Related
- 1999-02-01 JP JP2000529330A patent/JP3283032B2/ja not_active Expired - Fee Related
- 1999-02-01 EP EP99901979A patent/EP1058683B1/en not_active Expired - Lifetime
- 1999-02-01 WO PCT/KR1999/000051 patent/WO1999038862A1/en not_active Ceased
- 1999-02-01 CN CNB99802581XA patent/CN1158277C/zh not_active Expired - Fee Related
- 1999-02-01 ES ES99901979T patent/ES2185307T3/es not_active Expired - Lifetime
- 1999-02-01 BR BR9908545-3A patent/BR9908545A/pt not_active Application Discontinuation
- 1999-02-01 PT PT99901979T patent/PT1058683E/pt unknown
- 1999-02-01 US US09/601,426 patent/US6436960B1/en not_active Expired - Fee Related
- 1999-02-01 AT AT99901979T patent/ATE229017T1/de not_active IP Right Cessation
- 1999-02-01 AU AU21886/99A patent/AU745855B2/en not_active Ceased
- 1999-02-01 CA CA002320233A patent/CA2320233C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1158277C (zh) | 2004-07-21 |
| EP1058683A1 (en) | 2000-12-13 |
| DE69904302T2 (de) | 2003-08-14 |
| JP2002501918A (ja) | 2002-01-22 |
| AU745855B2 (en) | 2002-04-11 |
| CN1289331A (zh) | 2001-03-28 |
| CA2320233A1 (en) | 1999-08-05 |
| PT1058683E (pt) | 2003-04-30 |
| AU2188699A (en) | 1999-08-16 |
| ATE229017T1 (de) | 2002-12-15 |
| ES2185307T3 (es) | 2003-04-16 |
| JP3283032B2 (ja) | 2002-05-20 |
| DE69904302D1 (de) | 2003-01-16 |
| CA2320233C (en) | 2004-07-27 |
| WO1999038862A1 (en) | 1999-08-05 |
| US6436960B1 (en) | 2002-08-20 |
| EP1058683B1 (en) | 2002-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE229017T1 (de) | Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung | |
| BR0108893A (pt) | Composição farmacêutica, composto e processo de preparação de compostos | |
| KR950017957A (ko) | 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체 | |
| NO950297D0 (no) | Prolinamidderivater | |
| EP1362846A4 (en) | AMINOETHANOL DERIVATIVES | |
| BR0112224A (pt) | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto | |
| BR0211201A (pt) | Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero | |
| IL151172A0 (en) | Amine derivatives, their preparation and use as bax modulators | |
| ATE260255T1 (de) | 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate | |
| DE69635996D1 (de) | Pharmazeutische zusammensetzungen mit hydroximsäurederivaten | |
| MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
| EP1208092A4 (en) | SULPHONAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | |
| NO20040881L (no) | Orale antidiabetes midler. | |
| CA2406266A1 (en) | A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds | |
| EP1169320A4 (en) | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROL STRUCTURE AND METHOD FOR THEIR PRODUCTION | |
| PT992509E (pt) | Novos derivados macrolidos | |
| TR200000153T2 (tr) | İl-5 inhibite eden 6-azaurasil türevleri. | |
| EP1123923A4 (en) | DIHYDROPYRIDINE DERIVATIVES AND DRUG BLOCK CONTAINING THESE | |
| DK0913151T3 (da) | Anti-helicobacter Pylori-præparater indeholdende 1-methylcarbapenemderivater som den aktive bestanddel | |
| HUP0004900A2 (hu) | Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények | |
| ES2118650T3 (es) | Derivados de la quinolina-4-carbonilguanidina, procedimiento para la preparacion de los mismos y preparaciones farmaceuticas que contienen los compuestos. | |
| KR950701329A (ko) | 벤조티아졸술폰아미드 유도체, 그의 제조법 및 그 용도(Benzothiazolesulfornamide derivative, method for preparing the same, and use thereof) | |
| BR0109252A (pt) | Composto, processo para produzir um composto, composição farmacêutica, e, uso de um composto ou de uma composição | |
| UY26971A1 (es) | Nuevos antagonistas de neuroquinina, procedimiento para su preparación y composiciones farmacéuticas que contienen estos compuestos | |
| DE69908855D1 (de) | 9a, 11b-dehydro Derivative von 9-oxime-3-keto-6-0-methylerythromycin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 8O, 24 E 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |